NeuroScientific Biopharmaceuticals has secured key US backing for its Phase 2 stem cell Crohn’s trial, green-lighting a planned year-end start subject to regulatory, manufacturing and operational requirements.

NeuroScientific Biopharmaceuticals has appointed Southern Star Research to run its phase two clinical trials on its StemSmart treatment in refractory Crohn’s disease. Credit: File Perth-based NeuroScientific Biopharmaceuticals (ASX: NSB) has appointed leading Australian clinical research organisation (CRO) Southern Star Research to manage its planned phase two clinical trial for refractory Crohn’s disease in Australia and the United States. The appointment is a key oper

Microbial growth growing inside a petri dish Credit: File In biotech, discovering something that can change medicine might just be the easy part. Getting it from a laboratory bench into a hospital, or pathology clinic can actually present as many, if not more challenges than uncovering the discovery itself. Imagine a hypothetical ASX junior we’ll call XYZ Bio. Its scientists have discovered a molecule they believe could treat an aggressive cancer. Laboratory results loo

NeuroScientific Biopharmaceuticals has locked in a Pre-Investigational New Drug meeting with the US Federal Drug Administration ahead of its Phase 2 trial for its StemSmart product in treating Crohn’s disease. Credit: File Perth-based biotech NeuroScientific Biopharmaceuticals (ASX: NSB) has bagged a crucial meeting with the United States Food & Drug Administration (FDA) as it looks to push its patented “StemSmart” technology into a Phase 2 clinical trial in the lucrative

NeuroScientific Biopharmaceuticals has reported an 80% response rate from five Crohn’s disease patients treated with its StemSmart cell therapy, with all patients improving and no serious adverse events.

NeuroScientific Biopharmaceuticals has begun transferring production of its StemSmart stem cell therapy to Q-Gen in Brisbane, a key step towards phase two trials on Crohn’s disease and future commercial supply.

NeuroScientific Biopharmaceuticals’ StemSmart cell therapy has delivered real-world promise for those living with chronic Crohn’s disease, validating the platform and setting the stage for later-phase trials.

NeuroScientific Biopharmaceuticals chief executive officer Nathan Smith. Credit: File NeuroScientific Biopharmaceuticals (ASX: NSB) has medicated a fourth fistulising Crohn’s disease patient with its unique “StemSmart” stem-cell therapy, in a key step forward for the company’s game-changing treatment of the debilitating bowel condition. Approvals have already been secured to provide the unapproved therapy using the Therapeutic Goods Administration’s (TGA) special access sche

NeuroScientific Biopharmaceuticals’ stem cell therapy helped 80 per cent of a small group of patients retain their donor kidneys, which...

NeuroScientific Biopharmaceuticals is transferring its patented tech to one of Australia’s most experienced stem cell manufacturers to...

Melbourne-based Nathan Smith will bring his extensive commercial, operation and strategic experience in developing stem cell therapies to...

Neuroscientific Biopharmaceuticals has appointed respected paediatric haematologist and oncologist Dr Catherine Cole as its chief medical...

Haematology medical scientist Dr Marian Sturm, NeuroScientific’s incoming chief scientific officer, pioneered the development of the...

This week’s Bulls N’ Bears ASX Runner of the Week is… Grand Gulf Energy, after the company acquired an option over a potential billion-barrel oil prospect off the coast of Namibia.